* Hoth Therapeutics Inc is expected to report results on May 15 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Hoth Therapeutics Inc is for a loss of 54 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 3.8% in the last three months.
* Wall Street's median 12-month price target for Hoth Therapeutics Inc is $4.00, above its last closing price of $1.52.
This summary was machine generated March 29 at 20:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments